TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type III spinal muscular atrophy~* Be able to stand on the vibration platform with or without support~* Be able to undertake clinical examination and DXA evaluation~* Informed consent by the participant's parent/ guardian~Exclusion Criteria:~* There is a history of fracture within 8 weeks of enrolment of the present study and acute thrombosis, muscle or tendon inflammation, renal stones, discopathy or arthritis as reported by their parent/ guardian.~* There is a history of using any of the following medications, regardless of dose, for at least 1 month, within 3 months of enrolment into the present study: anabolic agents, or growth hormone.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1) Breast cancer diagnosis 2) Planning to receive chemotherapy treatment with paclitaxel in the curative setting (adjuvant or neoadjuvant) on a weekly or bi-weekly schedule~Exclusion Criteria:~1)Diabetes or other neurological disorder 2) Current or previous peripheral neuropathy 3)Previous treatment with paclitaxel 4)Active deep vein thrombosis (DVT) within last 12 months or history of untreated lower extremity DVT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Massage Therapy (Type: EXPERIMENTAL): Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have histologically confirmed squamous cell, adenosquamous or adenocarcinoma of the cervix~* Subjects must have non-metastatic FIGO Stage Ia-IVa cervical cancer~* Claustrophobic subjects must agree to be sedated during MRI procedures~* ECOG performance status of 0-2~Exclusion Criteria:~* Subjects with an inability to tolerate MR imaging~* Subjects who have had prior surgery for treatment of disease other than exploratory laparotomy or biopsy~* Study subjects who have contraindication to MRI scanning such as but not limited to subjects with pacemakers, metal fragments in the eye or certain metallic implants~* Women of childbearing potential who have a positive result on screening serum pregnancy test

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Cardiac Rehabilitation in Patients Heart Failure and Preserved Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. NYHA class II or III symptoms~2. Referred by physician to CR with echocardiographic evidence of HFpEF defined as an ejection fraction ≥ 50 % and moderate to severe (grade II-III) diastolic dysfunction.~3. ≥ 50 years of age~4. Free of orthopedic or other medical problems that would limit participation in CR~5. Peak VO2 on baseline cardiopulmonary exercise test (CPX) \< 24 mL/kg/min in men and \<21 mL/kg/min in women~Exclusion Criteria:~1. Systolic dysfunction, per ejection fraction \< 50%; those with mild (grade I) diastolic dysfunction~2. Initial clinical responses observed during first 3 visits in CR or baseline exercise test that would preclude participation in study over-all (e.g., new onset/troublesome arrhythmia that warrants further investigation) or undergoing HIIT (e.g., claudication, balance issue)~3. Patients with exercise induced angina during CR or CPX testing or ST segment depression representative of myocardial ischemia during CPX testing~4. Pregnant or planning to become pregnant~5. Any patient recently hospitalized for heart failure will have to wait at least 2 weeks before starting CR, or until clinically stable per physician(whichever time period is greater)~6. Atrial fibrillation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Higher Intensity Interval Training (HIIT) (Type: EXPERIMENTAL): None
- Moderate Continuous Training (MCT) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of non-small cell lung cancer~* measurable or evaluable disease~* primary tumor must be documented by histopathic analysis~* disease recurrences occurring greater than five years after original diagnosis must be biopsy proven~* treatment with only one prior chemotherapy regimen for advanced disease (one additional prior regimen was allowed for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant therapy)~* serum creatinine \< 2mg/dl, or a calculated creatinine clearance \> 40cc/min using the following formula: (140-age) x WT(kg) x 0.85 (if female 0.72) x creatinine (mg/dl). Tests must be done within 28 days prior to registration~* must have a CT scan (chest \& abdomen) within 4 weeks prior to registration~* Zubrod performance status of 0-3~Exclusion Criteria:~* women who are pregnant or nursing~* no other prior malignancy is allowed except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years~* history of ventricular fibrillation, sinus node or AV nodal disease, Wolff Parkinson White Syndrome, evidence of congestive heart failure, chest pain with exertion, hemodynamically significant or life threatening cardiac arrhythmia, or evidence of prior myocardial infarction on EKG. EKG must have been done within 28 days prior to registration. A normal cardiac stress test within 182 days prior to registration is required for all patients over 50 years old or those with abnormal EKG or any history of cardiac disease.~* hypersensitivity to erlotinib and/or Digoxin~* abnormal levels of K, Mg, and/or Ca, or conditions which cause such abnormalities (e.g. malnutrition, severe diarrhea, prolonged vomiting, dialysis, GI suction, untreated hypothyroidism, and use of diuretics, amphotericin B, steroids, or antacids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib and Digoxin (Type: EXPERIMENTAL): Erlotinib plus Digoxin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Harmonic Scalpel Vs. Electrocautery in Breast Reduction Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are eligible for enrollment if they agree to provide informed consent, can read and speak English, are at least 18 years of age, and are in generally good health.~Exclusion Criteria:~* under 18 years of age

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Harmonic Reduced Breast (Type: EXPERIMENTAL): harmonic scalpel used to reduce breast on that side
- Electrocautery Reduced Breast (Type: ACTIVE_COMPARATOR): Electrocautery (current practice = control) used to reduce breast on that side

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients.~* Age 65 years or older.~* Fibromyalgia diagnosed according to ACR 1990 criteria.~* Pain Score ≥ 10 on Gracely scale at screening and baseline assessments.~* Discontinuation of other dual-acting antidepressant medications, including duloxetine, venlafaxine, and tricyclic antidepressants for a period not less than 4.5 times the drug half-life as of the baseline evaluation.~Exclusion Criteria:~* Uncontrolled hypertension (BP ≥ 140/90) at screening or baseline evaluations.~* Baseline orthostasis (documented drop in SBP ≥ 20 mmHg or in DBP ≥ 10 mmHg within 3 minutes after standing) at screening or baseline evaluations.~* Psychosis, active suicidality, current episode of major depression or other severe psychiatric illness, or current alcohol/substance abuse or dependence as assessed by the MINI.~* Significant cardiovascular disease, including atrial fibrillation or other dysrhythmia, congestive heart failure, valvular heart disease, or QTc prolongation on baseline EKG (\> 450 msec).~* Uncontrolled narrow angle glaucoma.~* History of seizures.~* Use of MAO inhibitor drugs within the last 14 days.~* Abnormal baseline liver or renal function tests.~* Dementia or other syndrome of cognitive impairment that could interfere with the subject's ability to participate fully in the assessment protocol.~* Obstructive uropathy in males.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Milnacipran (Type: EXPERIMENTAL): Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Music as a Nonpharmacologic Approach to Pain Control With Intrauterine Device Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form~* Nulliparous adult females age 18 years or older (nulliparous is defined as no prior pregnancies greater than or equal to 20 weeks of gestation)~* English-speaking patients~* Undergoing insertion of a copper or levonorgestrel intrauterine device~* Willing to comply with all study procedures~Exclusion Criteria:~* Non-English speaking patients~* Patients with a support person in the room during IUD insertion~* Patients desiring a paracervical block for analgesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Music Intervention group (Type: EXPERIMENTAL): Subjects randomized to the music group will choose 10 songs, which will be played during the procedure, from the time of positioning through completion of IUD insertion and speculum removal. Participants will otherwise undergo standard protocol for IUD insertion in an outpatient clinic setting. Total participation is predicted to last approximately 30 minutes.
- Control group (Type: NO_INTERVENTION): Participants to undergo same standard protocol for IUD insertion in an outpatient clinic setting. No music will be played during the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Fecal Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male or female patient with inadequate relief of fecal incontinence symptoms after documented management in the primary care setting. They must have:~* a mini-mental status score of \> 18~* an up and go test score of \< 30 seconds~* bowel habit diary showing \> one episode of fecal incontinence episode per week~Exclusion Criteria:~* patients who previously underwent a course of biofeedback for fecal incontinence~* age \< 18 years~* major neurological disease~* significant cognitive impairment (mini mental status examination score \< 18), functional impairment (up and go score of \> 30 seconds)~* active inflammatory bowel disease~* history of spinal cord injury~* rectal resection~* ileal pouch procedures~* latex allergy~* significantly distressed and unable to consider informed consent issues adequately~* needing urgent medical referral~* insufficient written English skills to complete the questionnaires~* require surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
- Arm 2 (Type: EXPERIMENTAL): Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
The inclusion and exclusion criteria for the patients who participated in lead-in Study 14362A will be transferred from the 14362A study and for the patients who did not participate in lead-in Study 14362A the inclusion/exclusion is separately listed below.~Inclusion Criteria:~1. The patient has a diagnosis of Dravet Syndrome supported by:~   1. onset of seizures in the first year of life~  2. history of fever-induced prolonged seizures as determined by the Investigator~      * these may include prolonged (approximately 15 minutes or longer) hemi-clonic seizures~  3. multiple seizure types which may include:~      * generalised tonic-clonic (required for inclusion)~     * clonic (required for inclusion)~     * myoclonic jerks/seizures~  4. history of normal development prior to seizure onset followed by development delay or regression after seizure onset~  5. abnormal EEG consistent with Dravet Syndrome~2. The patient is currently receiving a stable dose of clobazam of at least 0.5 mg/kg/day (maximum 20 mg/day) for at least 3 months~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Clobazam (Type: EXPERIMENTAL): A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic hepatitis C naive to treatment~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with hepatitis C (Type: None): Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with alopecia areata by either:~  * A board-certified dermatologist, OR~ * Dermatology Nurse Practitioner, OR~ * Skin punch biopsy~* Patient has at least 2 alopecic patches each measuring at least 2 cm2 and are...~  * Located on contralateral body sites OR~ * Within the same body site but separated by ≥ 1 cm~* Patient is a candidate for intralesional triamcinolone.~* Patient able to give informed assent under IRB approval procedures when appropriate.~* At least one parent or guardian is able to provide informed consent.~Exclusion Criteria:~* Patient has alopecia totalis, alopecia universalis, or alopecia areata with ophiasis pattern.~* Known allergy or hypersensitivity to triamcinolone acetonide~* Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.~* Patient is unable/unwilling to provide informed assent when applicable.~* Known medical diagnosis or use of a medication that alters pain response at time of injection.~* Active infection at site designated for injection.~* If currently being treated for alopecia areata, the current treatment regimen has been started within less than 4 weeks of screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- MedJet Device (Type: EXPERIMENTAL): The Med-Jet-MBX needle-free injector (Med-Jet) is a novel, needle-free drug-delivery system, which we believe may be a solution to the pain and fear associated with needles. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region (MedJet) The drug-delivery device is highly configurable allowing adjustable depth and volume parameters (MedJet). In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas (MedJet).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy